By Chemical Treatment Patents (Class 435/238)
  • Publication number: 20120034678
    Abstract: Compounds of the formula I: including any possible stereoisomers thereof, or a pharmaceutically acceptable salt and/or solvate thereof, as well as pharmaceutical formulations and the use of compounds of formula I as HCV inhibitors.
    Type: Application
    Filed: April 23, 2010
    Publication date: February 9, 2012
    Inventors: Samuel Dominique Demin, David Mc Gowan, Stefaan Julien Last, Pierre Jean-Marie Bernard Raboisson
  • Publication number: 20120035198
    Abstract: Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.
    Type: Application
    Filed: July 8, 2011
    Publication date: February 9, 2012
    Inventors: Mohammad Javad Aman, Sina Bavari, James C. Burnett, Kelly Lyn Warfield
  • Publication number: 20120028887
    Abstract: The invention provides lipophilic conjugates comprising a short isolated peptide coupled to a hydrophobic moiety, the peptide comprising a sequence derived from the HIV-1 gp41 N-terminal heptad repeat domain, said peptide after conjugation to the hydrophobic moiety possesses anti-fusogenic activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV.
    Type: Application
    Filed: March 28, 2010
    Publication date: February 2, 2012
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Yechiel Shai, Yael Wexler-Cohen
  • Publication number: 20120014913
    Abstract: This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 19, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Shashank Shekhar, Thaddeus S. Franczyk, David M. Barnes, Travis B. Dunn, Anthony R. Haight, Vincent S. Chan
  • Publication number: 20120015424
    Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.
    Type: Application
    Filed: November 20, 2009
    Publication date: January 19, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Keith Selvitelli, Justin McCue
  • Patent number: 8088392
    Abstract: The present invention provides methods for the use of viral capsid proteins and chaperone proteins to produce immunogenic macro-molecular structures as antigen carrier to carry desired epitopes or antigens, for enhancing the immunogenicity of the carried epitopes or antigens for therapeutic or prophylactic vaccination. The immunogenic macro-molecular structures may also be used for therapeutic or prophylactic vaccination.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: January 3, 2012
    Inventor: Yunxu Cao
  • Publication number: 20110318352
    Abstract: The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized a-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.
    Type: Application
    Filed: July 23, 2010
    Publication date: December 29, 2011
    Applicant: DANA FARBER CANCER INSTITUTE, INC.
    Inventor: Loren D. Walensky
  • Publication number: 20110313022
    Abstract: The invention relates to compositions and methods for preventing and diminishing virus infection. The invention further relates to compositions and methods for diminishing inflammation associated with viral infection. The invention also relates to compositions and methods for interfering with TLR activation, and thereby diminishing inflammation associated with viral infection.
    Type: Application
    Filed: December 17, 2009
    Publication date: December 22, 2011
    Inventors: Peter D. Katsikis, Alina G. Boesteanu, Sefik Alkan
  • Publication number: 20110311569
    Abstract: This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against abroad spectrum of HIV-I isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-I. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-I primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-I entry into cells, as well as methods of treatment using the inhibitors.
    Type: Application
    Filed: July 10, 2007
    Publication date: December 22, 2011
    Inventor: Abraham Pinter
  • Publication number: 20110300104
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 8, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Hui Cao, Xiaowen Peng, Datong Tang, Yat Sun Or
  • Publication number: 20110263535
    Abstract: A tyrosine-based (phosphonylmethoxyalkyl)purine or -pyrimidine conjugate is provided. In some embodiments, the conjugate includes tyrosine based amino acid or dipeptide moieties of (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl)adenine or its cytosine analogue. A method of synthesizing such conjugates based on Boc-protected amino acid or dipeptides is also provided. In addition, a method of isomerizing an (S,S)-diastereoisomer to an (S,R)-diastereoisomer of an amino acid-based or dipeptide-based conjugate by a process including transesterification is provided. A method of inhibiting viral infection and a method of treating viral infection based on (phosphonylmethoxyalkyl)purine or -pyrimidine conjugates is also provided.
    Type: Application
    Filed: April 23, 2011
    Publication date: October 27, 2011
    Inventors: Charles E. McKenna, Boris A. Kashemirov, Ivan S. Krylov, Michaela Serpi, Valeria M. Zakharova, Larryn W. Peterson, John M. Hilfinger
  • Publication number: 20110250172
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 13, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Yat Sun Or
  • Patent number: 8034356
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: October 11, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Anton Mayr, Barbara Mayr
  • Publication number: 20110243897
    Abstract: The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups.
    Type: Application
    Filed: December 11, 2008
    Publication date: October 6, 2011
    Inventors: Leonard William Seymour, Karel Ulbrich
  • Publication number: 20110217330
    Abstract: The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuclease and ii) a DNA alkylating agent.
    Type: Application
    Filed: November 3, 2009
    Publication date: September 8, 2011
    Inventors: Bruno Rene Andre, Benoit Paul Suzanne Champluvier, Bénédicte Van Der Heyden
  • Publication number: 20110212056
    Abstract: Provided herein are methods for treatment of a liver disease by administering a combination of a matrix metalloproteinase inhibitor and a caspase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the MMP and caspase inhibitors described herein. Further provided are methods for lowering an elevated level of liver enzymes.
    Type: Application
    Filed: May 9, 2011
    Publication date: September 1, 2011
    Inventor: Alfred P. Spada
  • Publication number: 20110183894
    Abstract: The present invention features methods of treating or preventing a viral infection in a subject, methods of inhibiting a virus in a biological sample, and methods of treating or preventing a viral infection caused by a virus in or on the skin or mucus membrane. The instant invention describes novel methods for treating viral infections, in particular infections caused by high mannose enveloped viruses, for example hepatitis C virus (HCV).
    Type: Application
    Filed: July 31, 2009
    Publication date: July 28, 2011
    Inventors: Barry O'Keefe, James B. Mcmahon, Kirk Gustafson, Yutaka Takebe
  • Publication number: 20110165120
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.
    Type: Application
    Filed: February 28, 2011
    Publication date: July 7, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Publication number: 20110150827
    Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Application
    Filed: December 17, 2010
    Publication date: June 23, 2011
    Applicant: Idenix Pharmaceuticals, Inc.
    Inventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy, Claire Pierra, Francois-Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean-Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux
  • Publication number: 20110150929
    Abstract: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism.
    Type: Application
    Filed: December 28, 2009
    Publication date: June 23, 2011
    Applicant: Eli Lilly and Company
    Inventors: Hassibullah Akeefe, Moiz Kitabwalla
  • Publication number: 20110142798
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 16, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Hui Cao, Lu Ying, Yat Sun Or
  • Publication number: 20110136210
    Abstract: Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production of beer, cider, wine, a biofuel, dairy product or any combination thereof. Also disclosed are in vitro methods for enhancing the growth of one or more probiotic microorganisms and methods of enhancing growth of a microorganism in a diagnostic test sample. Methods of inhibiting microbial activity are also disclosed. In one particular example, a method of inhibiting microbial activity includes selecting a medium that is susceptible to H1N1 influenza contamination; and contacting the medium with MSM at a concentration of about 10% to about 16% of weight by volume, thereby inhibiting H1N1 influenza microbial activity.
    Type: Application
    Filed: February 16, 2011
    Publication date: June 9, 2011
    Inventors: Rodney L. Benjamin, Jeffrey Varelman, Anthony L. Keller
  • Publication number: 20110129443
    Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Application
    Filed: August 4, 2010
    Publication date: June 2, 2011
    Applicant: Idenix Pharmaceuticals, Inc.
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Frederic Leroy, Thierry Convard, Dominique Surleraux
  • Publication number: 20110123496
    Abstract: The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 19, 2010
    Publication date: May 26, 2011
    Inventors: Yonghua Gai, Yat Sun Or, Guoqiang Wang
  • Publication number: 20110124703
    Abstract: The invention concerns molecules with a bis-(heteroaryl)maleimide structure and having inhibiting characteristics with respect to enzymes with a catalytic pocket comprising the invariant amino acids D, D and E or D, D and D, such as transposases, RAG recombinases or retroviral integrases. The invention also concerns the use of said molecules for in vitro, ex vivo or in vivo inhibition of transposases, RAG recombinases and retroviral integrases such as HIV integrase, as well as the use of said molecules in the treatment of diseases associated with these enzymes in an animal or human host, in particular in the treatment of AIDS.
    Type: Application
    Filed: February 3, 2009
    Publication date: May 26, 2011
    Inventors: Marie-Claude Viaud-Massuard, Jérôme Guillard, Yves Bigot, Corinne Auge-Gouillou
  • Publication number: 20110118334
    Abstract: The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 19, 2011
    Applicant: AVI BIOPHARMA, INC.
    Inventor: Patrick L. Iversen
  • Publication number: 20110110975
    Abstract: The present invention is a composition comprising a live virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. The present invention further provides a method for deactivating a live virus having an infectious component and a plurality of surface antigens, comprising the steps of: a) providing a live virus having an infectious component and a plurality of surface antigens; and b) contacting the virus with a formaldehyde donor agent having a molecular weight that is greater than about 50 g/mol and less than about 400 g/mol for a period of time (e.g., at least about 12 hours) sufficient for de-activating the infectious component with the formaldehyde donor agent and for preserving at least a portion of the surface antigens to form a deactivated virus.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 12, 2011
    Applicant: Streck, Inc.
    Inventors: James A. Grunkemeyer, Wayne L. Ryan
  • Patent number: 7939085
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: May 10, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Anton Mayr, Barbara Mayr
  • Publication number: 20110105423
    Abstract: The present invention relates to compounds that modulate the replication of negative-sense, single-stranded RNA viruses, such as influenza virus, and the use of such compounds. The invention relates to methods for increasing the titer of negative-sense, single-stranded RNA viruses, such as influenza virus, in substrates for virus propagation (e.g., tissue culture). The invention also relates to the use of compounds that decrease virus replication as antiviral agents. The invention further relates to methods for identifying compounds that modulate the replication of negative-sense, single-stranded RNA viruses, in particular, influenza virus.
    Type: Application
    Filed: March 6, 2009
    Publication date: May 5, 2011
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
    Inventors: Megan L Shaw, Hans-Heinrich Hoffmann, Adolfo Garcia-Sastre, Peter Palese
  • Publication number: 20110081700
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Application
    Filed: July 30, 2010
    Publication date: April 7, 2011
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Publication number: 20110070196
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 24, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
  • Publication number: 20110070197
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 24, 2011
    Inventors: Yat Sun Or, Lu Ying, Xiaowen Peng, Ce Wang, Yao-Ling Qiu
  • Publication number: 20110070193
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: March 17, 2010
    Publication date: March 24, 2011
    Applicant: Abbott Laboratories
    Inventors: Rolf Wagner, Warren M. Kati, Dachun Liu, Yaya Liu, Kenton L. Longenecker, Clarence J. Maring, John K. Pratt, Todd W. Rockway, Kent D. Stewart, Michael D. Tufano
  • Publication number: 20110064697
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 17, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
  • Publication number: 20110059040
    Abstract: Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers.
    Type: Application
    Filed: June 26, 2008
    Publication date: March 10, 2011
    Inventors: Patrick F. Kiser, Julie I. Jay, Meredith C. Roberts
  • Publication number: 20110046982
    Abstract: Disclosed herein are compounds, compositions and methods related to viral inhibition. In some forms, the compounds, compositions and methods are related to binding RNA.
    Type: Application
    Filed: August 16, 2010
    Publication date: February 24, 2011
    Applicant: CLEMSON UNIVERSITY RESEARCH FOUNDATION (CURF)
    Inventors: Dev P. Arya, Nihar Ranjan, Sunil Kumar
  • Publication number: 20110045103
    Abstract: The present invention pertains to methods of inactivating human immunodeficiency virus (HIV), both in vitro and in vivo. Such methods also relate to treating HIV-related symptoms and the treatment of acquired immune deficiency syndrome in patients. Methods typically employ administering a composition comprising ammonium chloride such that HIV is inactivated.
    Type: Application
    Filed: August 19, 2010
    Publication date: February 24, 2011
    Inventor: Abdul R. Abukurah
  • Patent number: 7892562
    Abstract: Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psoralen inactivated HIV. The number of doses is 3X. The starting dose for an adult is 1x109-1x1010. The starting dose for an adolescent is ½(1x109-1x1010). The starting dose for a pediatric patient is ¼(1x109-1x1010). The second dose will consist of 1/10th of starting concentrations. The third dose will consist of 1/100th of starting concentrations. This will facilitate a Th-1 response. The days of administration are days 1; 30; and 180. Alternatively the days of administration are days 1; 20-40; and 160-200. The site of administration is one that targets lymphatic tissue. Adjuvant is administered before, simultaneous with or after each dose of the immunogenic compositions.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: February 22, 2011
    Inventor: Nelson M. Karp
  • Publication number: 20110038890
    Abstract: The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 17, 2011
    Inventors: Yossef Raviv, Julie M. Belanger, Mathias Viard, Robert Blumenthal, Julian W. Bess, JR.
  • Publication number: 20110027316
    Abstract: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus.
    Type: Application
    Filed: November 21, 2008
    Publication date: February 3, 2011
    Applicant: Wyeth Farma, S.A.
    Inventor: Joan Plana Duran
  • Patent number: 7879800
    Abstract: A process suitable for processing scaled-up amounts of source material in the range of tens of kilograms for the purification of alpha-1 proteinase inhibitor (API) from a mixture of unpurified proteins is provided. More particularly, a process for the purification of API from blood plasma or from plasma fractions to obtain pharmaceutical grade API on a commercial scale is provided. The API produced by the process is highly pure (at least 90% API out of the total protein) and highly active (at least 90% active API). Pharmaceutical compositions comprising the purified API and methods of using same are also described.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: February 1, 2011
    Assignee: Kamada Ltd.
    Inventor: Shabtai Bauer
  • Publication number: 20110020393
    Abstract: The present inventors improved methods for inactivating Japanese encephalitis virus vaccines, and assessed the safety of vaccines produced by combining multiple vaccines. The present inventors successfully produced safer Japanese encephalitis vaccines by cell culture, which can be stored more stably over a long period than conventional Japanese encephalitis vaccines. Furthermore, it is also expected that the production methods can be used to produce other viral vaccines with excellent storage stability.
    Type: Application
    Filed: December 26, 2008
    Publication date: January 27, 2011
    Inventors: Tomoyoshi Komiya, Hiroko Toriniwa
  • Publication number: 20110014234
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Application
    Filed: September 28, 2010
    Publication date: January 20, 2011
    Inventors: Anton Mayr, Barbara Mayr
  • Publication number: 20110014233
    Abstract: A method to prepare inactivate viral vaccine by exposing the virus to a predetermined concentration of an inactivating psoralen, and a preselected intensity of ultraviolet radiation for a time period sufficiently long to render the virus non-infectious but less than that which would result in degradation of its antigenic characteristics.
    Type: Application
    Filed: July 17, 2010
    Publication date: January 20, 2011
    Inventors: Tadeusz J. Kochel, Ryan C. Maves, Kevin Porter
  • Publication number: 20110014230
    Abstract: A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
    Type: Application
    Filed: March 18, 2009
    Publication date: January 20, 2011
    Applicant: NOVARTIS AG
    Inventors: Christoph Haussmann, Frank Hauschild, Bjorn Jobst
  • Publication number: 20110008384
    Abstract: Compounds having unique antiviral properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from Fomitopsis and blends of medicinal mushroom species and are useful in preventing and treating viruses including Poxviridae and Orthopox viruses.
    Type: Application
    Filed: March 27, 2007
    Publication date: January 13, 2011
    Inventor: Paul Edward Stamets
  • Publication number: 20100279968
    Abstract: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs.
    Type: Application
    Filed: December 27, 2006
    Publication date: November 4, 2010
    Applicant: Koronis Pharmaceuticals, Inc.
    Inventors: Ling Li, Alexander Gall, Richard Daifuku
  • Publication number: 20100278858
    Abstract: Provided is a process for preparing attenuated viral strains, comprising to contact, at least one sulphated polymer and a virus susceptible to the inhibition of the polymer, via successive passages of the virus with increasing polymeric concentrations, where the amenable virus is characterized by the method of reducing viral plates and where the strain resulting from the attenuated virus has stable phenotypic and genotypic characteristics, different from that of the virus strain in wild state that generated thereto. The process comprises to contact the sulphated polymer(s) with the virus susceptible to the inhibition of the polymer via about 15 or more successive passages with increasing concentrations of the sulphated polymer(s). According to the inventive process, the concentration of the at least one sulphated polymer in the first passage should be less than the IC50 of the polymer for the amenable virus when it is found in wild state.
    Type: Application
    Filed: November 19, 2008
    Publication date: November 4, 2010
    Applicant: INIS BIOTECH LLC
    Inventors: María Josefina Carlucci, Elsa Beatriz Damonte, Carlos Alberto Pujol, Alberto Saúl Cerezo, Marina Ciancia
  • Publication number: 20100260710
    Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Application
    Filed: April 7, 2010
    Publication date: October 14, 2010
    Applicant: Idenix Pharmaceuticals, Inc.
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Michel Derock, Frederic Leroy, Jean-Christophe Meillon, Thierry Convard, Dominique Surleraux
  • Publication number: 20100260798
    Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 14, 2010
    Applicant: SANOFI PASTEUR
    Inventors: Virginie Fabre, Céline Rocca, Pierre Riffard, Eric Calvosa